Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Seres Therapeutics stock
Learn how to easily invest in Seres Therapeutics stock.
Seres Therapeutics Inc is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Seres Therapeutics employs 333 staff and has a trailing 12-month revenue of around $136.7 million.
How to buy shares in Seres Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MCRB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Seres Therapeutics stock price (NASDAQ: MCRB)Use our graph to track the performance of MCRB stocks over time.
Seres Therapeutics shares at a glance
|Latest market close||$6.42|
|52-week range||$2.50 - $11.69|
|50-day moving average||$5.27|
|200-day moving average||$5.95|
|Wall St. target price||$13.14|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.94|
Buy Seres Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Seres Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Seres Therapeutics price performance over time
|1 week (2022-09-23)||9.00%|
|1 month (2022-09-01)||23.70%|
|3 months (2022-07-01)||76.86%|
|6 months (2022-03-28)||N/A|
|1 year (2021-10-01)||-11.33%|
|2 years (2020-10-01)||-76.82%|
|3 years (2019-10-01)||64.62%|
|5 years (2017-09-29)||16.04|
Seres Therapeutics financials
|Revenue TTM||$136.7 million|
|Gross profit TTM||$3 million|
|Return on assets TTM||-23.05%|
|Return on equity TTM||-166.19%|
|Market capitalisation||$744.4 million|
TTM: trailing 12 months
Seres Therapeutics share dividends
We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.
Seres Therapeutics share price volatility
Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $2.5 up to $11.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 3.01. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Seres Therapeutics overview
Seres Therapeutics, Inc. , a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center.
Frequently asked questionsWhat percentage of Seres Therapeutics is owned by insiders or institutions?
Currently 6.693% of Seres Therapeutics shares are held by insiders and 81.638% by institutions. How many people work for Seres Therapeutics?
Latest data suggests 333 work at Seres Therapeutics. When does the fiscal year end for Seres Therapeutics?
Seres Therapeutics's fiscal year ends in December. Where is Seres Therapeutics based?
Seres Therapeutics's address is: 200 Sidney Street, Cambridge, MA, United States, 02139 What is Seres Therapeutics's ISIN number?
Seres Therapeutics's international securities identification number is: US81750R1023 What is Seres Therapeutics's CUSIP number?
Seres Therapeutics's Committee on Uniform Securities Identification Procedures number is: 81750R102
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert